5 October 2020
The COVID-19 pandemic has interrupted clinical trials for both pharma and medical device companies and has also delayed the start of many new clinical projects.
On this background, it is prudent to revisit the current regulations governing clinical trials in Australia, China/HK and Singapore and examine whether there have been any regulatory relaxations for products showing promise for either the prevention (e.g. vaccines) or treatment (e.g. remdesivir) of the virus.
Our regional panel, comprising of Alison Wong (Head of Life Sciences APAC/Partner, Hong Kong & China), Anan Sivananthan (Partner, Singapore), Lynne Lewis (Partner, Sydney), and Dr. Anthony Wilkinson (Registered Foreign Lawyer, Hong Kong) will discuss the following topics for each jurisdiction:
-
The current pathways and time frames for registering clinical trials
-
The types of documentation required for registering clinical trials
-
The relative pros and cons of running clinical trials in each location
-
The effect of the COVID-19 pandemic on running clinical trials for products indicated for the prevention or treatment of COVID-19
As we would like to make the forum interactive, you will be able to ask questions during the forum through a chat box function, where we will pick up as many questions from the participants on these topics as time allows.
Please register from the RSVP button below. You will receive dial-in details a day before of the webinar.
Timings
10 am – Thailand
11 am – Hong Kong/China/Singapore/Malaysia/Australia (WA)
12 pm – Japan
1 pm – Australia (NSW, TAS, VIC, QLD)
Language
The webinar will be conducted in English.
Contact/ Registration
Alison Wong, Partner, Bird & Bird
alison.wong@twobirds.com
